AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 292 min read$ALNY

Alnylam anticipates $4.2B–$4.5B 2026 TTR sales, expands TRITON-CM to ~2,250 patients while keeping ~2030 launch timing (NASDAQ:ALNY)

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 product revenues of $1.3B, up 52% YoY, driven by AMVUTTRA uptake. CEO Yvonne Greenstreet anticipates 2026 TTR sales of $4.2B–$4.5B and expanded the TRITON-CM trial to ~2,250 patients, maintaining a 2030 launch timeline.

Original reporting
seekingalpha.com
Published Oct 29, 2026, 6:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ALNY
Bullish
high confidence
Mentioned
$ALNY
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ALNYBullishHigh
01

Why it matters

The guidance and patient expansion provide a fresh, material catalyst that could drive the stock higher.

02

Market read

First‑report guidance lift for a mid‑cap biotech, likely to generate buying interest.

03

What to watch

Potential regulatory hurdles for TRITON‑CM and competition from other TTR treatments.

Relevance 8/10Novelty 8/10Timing: today

Background

Alnylam's earnings call highlighted a 52% YoY revenue increase and strong uptake of its AMVUTTRA product.

Company-level read

Ticker impact

$ALNYBullishHigh confidence
Context

Alnylam disclosed 2026 TTR sales guidance of $4.2‑$4.5 B and expanded TRITON‑CM enrollment to ~2,250 patients.

Expected impact

potential upside as market prices in the strong 2026 sales outlook

Evidence & confidence

The new multi‑billion dollar sales forecast is material and not previously reported, creating a clear catalyst for price appreciation.

Market effects

Sector

Boosts outlook for the RNA‑interference therapeutic sector.

Regional

Positive for US biotech investors.

Global

May influence global biotech sentiment given Alnylam's leadership in TTR therapies.

Counterpoint

What could challenge this read

Skeptics may question demand sustainability and the timeline to 2030 launch.

Key entities

  • company
    Alnylam Pharmaceuticals

    US‑listed biotech firm (NASDAQ:ALNY) developing RNA‑i therapeutics.

Read at source← All news

Related articles

OCT 29
$ALNYMed

Alnylam Pharmaceuticals Q3 Earnings Call Highlights

Alnylam Pharmaceuticals reported that AMVUTTRA has access for 99% of covered lives, with 90% of patients within 10 miles of treatment. The company is monitoring a proposed CMS rule that could reduce Medicare reimbursement for 340B drugs, which represents a meaningful portion of its business. UnitedHealth implemented a restrictive policy for AMVUTTRA, potentially delaying access for new patients.

finance.yahoo.com2 min
OCT 29
$ALNYHighAI 8/10

Alnylam (ALNY) Q3 2026 Earnings Call Transcript

Alnylam (ALNY) reported Q3 2026 revenue of $1.46B, up 17% YoY, driven by TTR franchise growth. AMVUTTRA sales rose 65% YoY to $1.13B. Guidance for TTR product sales was lowered to the range of $4.2B-$4.5B. Management cited Medicare Advantage policy changes and 340B reimbursement adjustments as risks. TRITON-CM study enrollment target was expanded to 2,250 patients.

fool.com3 min
OCT 29
$ALNYMed

Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction”

Alnylam Pharmaceuticals (ALNY) shares fell 19% after expanding its nucresiran heart trial to 2,250 patients, citing confidence in positive results. Despite 52% product revenue growth, concerns arise about nucresiran's benefit. Analysts expect revenue growth through 2028, driven by AMVUTTRA. Competitors like Pfizer (PFE) and BridgeBio (BBIO) may gain if nucresiran's data is weak.

finance.yahoo.com2 min
OCT 29
$ALNYHighAI 8/10

Alnylam Reports 17% Q3 Revenue Growth, Expands Nucresiran Trial And Advances RNAi Pipeline

Alnylam Pharmaceuticals (ALNY) reported Q3 2026 revenue growth of 16.7% to $1.458 billion, driven by a 52% increase in global net product revenue, primarily from its TTR franchise. Net income rose to $2.167 billion. The company expanded its Phase 3 study for nucresiran and presented promising early data for brezosiran in Huntington's disease. Alnylam also advanced its pipeline with mivelsiran and ALN-5288 for neurological diseases.

rttnews.com3 min
OCT 29
$ALNYMedAI 8/10

Alnylam Pharmaceuticals Shares Update About Phase 3 Nucresiran Study, Reaffirms FY26 Outlook

Alnylam Pharmaceuticals (ALNY) updated its Phase 3 TRITON-CM study for nucresiran, expanding enrollment to 2,250 patients. The company aims for a 2030 launch, viewing it as key to long-term growth. Alnylam reaffirmed its FY26 outlook: $4.7B-$5.1B in product revenue, $575M-$625M in collaboration revenue, and $2.7B-$2.8B in R&D/SG&A expenses. ALNY stock fell 17.89% to $190.71.

rttnews.com1 min
OCT 29
$ALNYMed

Stifel downgrades Alnylam stock rating on Amvuttra concerns

Stifel downgraded Alnylam Pharmaceuticals (ALNY) to Hold from Buy, lowering its price target to $225 from $318. The firm cited concerns about Amvuttra's near-term performance and market challenges. Despite a strong Q3 2026 earnings beat, ALNY's stock fell due to guidance concerns and slower TTR franchise growth. The stock is near its 52-week low of $197.81, with a 79.7% gross profit margin.

investing.com2 min